Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

• Franck Rapaport,
• Kenneth Seier,
• Yaseswini Neelamraju,
• Duane Hassane,
• Timour Baslan,
• Daniel T. Gildea,
• Samuel Haddox,
• Tak Lee,
• H. Moses Murdock,
• Caroline Sheridan,
• Alexis Thurmond,
• Ling Wang,
• Martin Carroll,
• Larry D. Cripe,
• Hugo Fernandez,
• Christopher E. Mason,
• Elisabeth Paietta,
• Gail J. Roboz,
• Zhuoxin Sun,
• Martin S. Tallman,
• Yanming Zhang,
• Mithat Gönen,
• Ross Levine,
• Ari M. Melnick,
• Maria Kleppe,
• Francine E. Garrett-Bakelman

Affiliations

Franck Rapaport

Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center

Kenneth Seier

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center

Yaseswini Neelamraju

Department of Biochemistry and Molecular Genetics, University of Virginia

Duane Hassane

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine

Timour Baslan

Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

Daniel T. Gildea

Department of Biochemistry and Molecular Genetics, University of Virginia

Samuel Haddox

Department of Biochemistry and Molecular Genetics, University of Virginia

Tak Lee

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine

H. Moses Murdock

Division of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine

Caroline Sheridan

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine

Alexis Thurmond

Department of Biochemistry and Molecular Genetics, University of Virginia

Ling Wang

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine

Martin Carroll

Division of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine

Larry D. Cripe

Simon Cancer Center, Indiana University

Hugo Fernandez

Department of Malignant Hematology & Cellular Therapy, Moffitt Cancer Center

Christopher E. Mason

Department of Physiology and Biophysics, Weill Cornell Medicine

Elisabeth Paietta

Montefiore Medical Center

Gail J. Roboz

Weill Cornell Medicine and The New York Presbyterian Hospital

Zhuoxin Sun

Dana-Farber Cancer Institute

Martin S. Tallman

Memorial Sloan Kettering Cancer Center

Yanming Zhang

Department of Pathology, Memorial Sloan Kettering Cancer Center

Mithat Gönen

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center

Ross Levine

Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center

Ari M. Melnick

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine

Maria Kleppe

Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center

Francine E. Garrett-Bakelman

Department of Biochemistry and Molecular Genetics, University of Virginia